Movement Disorder
5 drugs3,540 FAERS reportsMedDRA PT
GET
/api/v1/reaction/movement-disorderReference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. The drugs below are ranked by how often this reaction appears on FAERS reports for each drug — high share does not mean the drug caused the reaction, and absence from this list does not mean the reaction never occurred. This is not a symptom checker.
DefinitionNLM MeSH D009069
Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.
Source: U.S. National Library of Medicine — MeSH (Movement Disorders)
Drugs reporting Movement Disorder (5)
Share = reports listing this reaction ÷ total matched reports for the drug. — means the upstream totals query failed at ingest and the denominator is unknown.
- 1Aluminum Zirconium Pentachlorohydrex Gly480%
- 2Opium217%
- 3Gadoxetate7317%
- 4Metoclopramide3,2724.3%
- 5Tetrabenazine1892.6%
Related reactions
Other reactions most often co-reported on the same drug set. Ranked by Jaccard similarity over drug-id sets — pure data-derived co-occurrence, not a clinical relationship.
Literature
Recent PubMed references pinned to Movement Disorders as a MeSH major topic. About the reaction term itself — not about any specific drug.
- Blm10/PA200-Activated 20S Proteasomes Promote α-Synuclein Degradation and Bypass Proteasome Inhibition in Parkinson's Disease Models.Aging cell · 2026 · Ali TT, Zhornyak A, Merghani M, et al.PMID 42206954DOI 10.1111/acel.70566
- Long-Term Surgical Outcomes and Influential Factors of Subthalamic Nucleus Deep Brain Stimulation for Dyskinesia in Parkinson's Disease: A 3-Year Longitudinal Cohort Study.Clinical interventions in aging · 2026 · Wang S, Xue T, Ma R, et al.PMID 42205153DOI 10.2147/CIA.S600031
- Genetic Variants and Clinical Characteristics of Young-Onset Parkinson's Disease in the Hakka Population of Western Fujian.Brain and behavior · 2026 · Pan LY, Guo F, Zheng C, et al.PMID 42204920DOI 10.1002/brb3.71504
- Urinary Biomarkers in Parkinson's Disease: A Structured Integrative Review of Pathophysiological Pathways.Medical sciences (Basel, Switzerland) · 2026 · Santos HQP, Sumita NM, Alberto-Silva C, et al.PMID 42201050DOI 10.3390/medsci14020258
- Comparing the Metabolic Profile of Patients Affected by Acute-Onset Neuropsychiatric Syndrome PANS and Tourette Syndrome: Preliminary Data.Medical sciences (Basel, Switzerland) · 2026 · Murgia F, Noto A, Tanca MG, et al.PMID 42201024DOI 10.3390/medsci14020232
- Sex Differences in the Treatment of People with Parkinson's Disease with a Device-Aided Therapy: A Prospective Real-World Study.Medical sciences (Basel, Switzerland) · 2026 · Santos García D, Solleiro Vidal Á, Blázquez Estrada M, et al.PMID 42201009DOI 10.3390/medsci14020217
Note. FAERS reports are voluntarily submitted and are NOT incidence rates, signals, or causal evidence. Counts reflect reporting volume, not how often a reaction occurs. Reference statistics only.